Propranolol plus immunotherapy and chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB-IV) non-small cell lung cancer that cannot be removed with surgery
- You have not had chemotherapy or immunotherapy for advanced disease before (prior treatment before the cancer spread is okay if it ended at least a year ago)
- Your cancer does not have specific gene changes (EGFR, ALK, or ROS1) – your doctor can check this from a biopsy
- You are able to take a beta-blocker (propranolol) – this means you don't have asthma, very slow heart rate, certain heart problems, or severe diabetes
- You have at least one tumor that can be measured on a CT scan or MRI, and your blood counts, liver, and kidney function are adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a blood pressure medicine (propranolol) to standard chemotherapy and immunotherapy before surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether giving a combination of two targeted drugs (tislelizumab and anlotinib) plus standard chemotherapy before and after surgery can help people with early-stage lung cancer. The goal is to see if this approach can shrink the tumor and lower the chance of the cancer coming back.
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.